Phase 2 Trial - Exenatide Treatment in Parkinson's Disease

[Farooqji]

The aim of this trial is to investigate the effect of Exenatide, 2 mg, subcutaneous injection, once weekly on disease progression represented by the change in longitudinal Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro- D-glucose (FDG-PET) in individual PD subjects, and to identify an Exenatide-related pattern in FDG-PET that will provide insight into the treatment-effect in the brain. The investigators chose the standard regimen prescribed in Type 2 Diabetes Mellitus (T2DM) and the regimen used in a recent trial in PD. The treatment period will be 18 months, and patients will be randomly assigned to either active treatment or placebo. Patients with PD diagnosis, stable on medication during the last year, and Hoehn and Yahr stage 2 or less will be evaluated for the inclusion.

clinicaltrials.gov/ct2/show...

[Parkinsonjisung]

Another one to the growing list. In 3 or 4 years time, we should have a pretty good understanding on where we stand on glp-1 and parkinson's.

[jrg54321]

One study center in Sweden.